Trial Profile
Phase Ib study of combination therapy with Cisplatin, Irinotecan, and Ramucirumab for extensive-disease small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Acronyms CIRCLE study
- 01 Feb 2022 Results published in the Lung Cancer
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 24 May 2021 Status changed from active, no longer recruiting to completed.